- What changed in NKTR news today?
- Nektar says Phase 3 ZENITH AD trial for rezpegaldesleukin expands into treatment-experienced patients: Nektar said its Phase 3 ZENITH AD trial for rezpegaldesleukin has expanded to include treatment-experienced patients. The company also presented one-year Phase 2b data and outlined further trial plans.
- Does Rallies summarize NKTR news?
- Yes. Rallies summarizes NKTR news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
- Is NKTR research on Rallies investment advice?
- No. Rallies provides research, data, and educational context for NKTR. It does not provide personalized investment advice.
